Hematologic Diseases, Hematologic Malignancies
Conditions
Keywords
Haploidentical stem cell transplantation, Graft-versus-host disease, Immune reconstitution, Alloreactive T-cells, Photodepletion, TH9402, Transplant related mortality, Hematologic malignancy
Brief summary
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety of the administration of donor lymphocytes depleted of alloreactive T-cells following a stem cell transplant from a related, haploidentical donor, in patients with severe hematologic malignancies.
Detailed description
Allogeneic stem cell transplantation is the treatment of choice for many patients with leukemia and other hematologic malignancies. However, a major limitation of this therapy is that for a significant number of patients no fully HLA-matched donor can be found. The application of partially HLA-matched (haploidentical) family donors, who are virtually always available, has some complications. If there is no T-cell add-back it increases the risk for life-threatening infections and disease relapse, while in case of T-cell add-back the risk of graft-versus-host disease is raised. Kiadis Pharma has developed a method to selectively deplete host alloreactive T-cells through photodynamic therapy, using TH9402 ex vivo. The donor lymphocyte preparation depleted of functional alloreactive T-cells (ATIR) are administered to the patient 4-6 weeks after the stem cell transplant. This method enables early immune reconstitution while preventing graft-versus-host disease.
Interventions
BIOLOGICALDonor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
Single intravenous infusion
Sponsors
Kiadis Pharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Any of the following hematologic malignancies: very high risk leukemia, acute leukemia, chronic myeloid leukemia (CML), lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS) * Incompatibility at two to three loci (HLA-A, B and/or DR) or a single DR locus of the unshared haplotype between the donor and recipient * Life expectancy of at least 3 months * Satisfactory performance status (ECOG ≤ 2);
Exclusion criteria
* Possibility of performing an allogeneic transplant with an HLA (human leukocyte antigen) matched sibling donor * Availability of an 6/6 HLA-A, B and DRB1 matched unrelated donor within 2-3 months; * Pregnancy * Viral hepatitis (B or C) * Active serious infectious process * HIV positivity; * Systemic dysfunction (cardiac, pulmonary, hepatic and renal) contra-indicating allogeneic stem cell transplantation * Prior allogeneic transplantation * Prior autologous transplantation within twelve months of baseline visit * Any abnormal condition or laboratory result that is considered by the principal investigator capable of altering patient condition or study outcome * Active central nervous system (CNS) disease at baseline * Participation in a trial with an investigational agent within 30 days prior to entry in the study * Malignant cells in circulating peripheral blood (\> 25%) * Other active malignant disease that would severely limit life expectancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose limiting toxicity, defined as acute graft-versus-host disease grade III or IV | Within 30 days after ATIR infusion |
Secondary
| Measure | Time frame |
|---|---|
| Immune reconstitution | Until 60 months after ATIR infusion |
| Rate of disease relapse | Until 60 months after ATIR infusion |
| Occurrence and severity of graft-versus-host disease | Until 60 months after ATIR infusion |
| Occurrence of adverse drug reactions | Until 18 months after ATIR infusion |
| Incidence and severity of infections | Until 18 months after ATIR infusion |
Countries
Canada
Outcome results
None listed